No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
501 |
4. Check minimum number of eventsNone |
501 |
5. Include endpointsNone |
501 |
6. Filter based on genotype QC (FinnGen only) |
501 |
Control definitions (FinnGen only)
- Control exclude
- H7_EYEOTH
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- H55-H59
- Name in latin
- Nystagmus et alii motus irregulares oculi
Similar endpoints
↥List of similar endpoints to
Nystagmus and other irregular eye movements
based on the number of shared cases.
Similar with more cases:
- Other disorders of eye and adnexa
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4714 | 2279 | 2421 |
| Only index persons | 3952 | 1959 | 1993 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.07 | 0.07 |
| Only index persons | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 25.97 | 30.97 | 21.18 |
| Only index persons | 32.97 | 36.00 | 30.00 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 501 | 300 | 201 |
| Unadjusted period prevalence (%) | 0.10 | 0.10 | 0.09 |
| Median age at first event (years) | 43.61 | 42.90 | 44.68 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 457
- Matched controls
- 4562
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
+∞
323.0
446
*
R42
ICD-10 Finland
Dizziness and giddiness
5.1
45.3
173
484
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.3
42.5
112
195
H53.2
ICD-10 Finland
Diplopia
19.1
34.5
53
31
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.6
34.3
95
174
G35
ICD-10 Finland
Multiple sclerosis
21.0
29.7
44
23
AA1AD
NOMESCO Finland
CT of head and brain
3.7
27.7
144
501
109
Kela drug reimbursment
Multiple sclerosis
23.5
26.0
37
17
XCK00
NOMESCO Finland
Perimetry
6.7
24.8
66
112
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
30.0
23.4
31
11
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
20.6
21.1
31
16
3795A
ICD-9 Finland
Other disorders of eye, Nystagmus and other irregular eye movements
+∞
21.0
20
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
21.0
119
432
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.9
20.4
71
166
H50.0
ICD-10 Finland
Convergent concomitant strabismus
18.7
19.8
30
17
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.3
19.6
77
204
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
19.8
18.9
28
15
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.8
18.8
55
105
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.8
17.5
79
236
H47.2
ICD-10 Finland
Optic atrophy
52.0
17.1
20
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
11.4
16.7
31
29
G40.9
ICD-10 Finland
Epilepsy, unspecified
7.6
16.7
39
55
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.4
16.6
63
160
H81.2
ICD-10 Finland
Vestibular neuronitis
12.3
15.7
28
24
Q12.0
ICD-10 Finland
Congenital cataract
+∞
15.7
15
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
15.4
94
352
R27.0
ICD-10 Finland
Ataxia, unspecified
46.6
15.1
18
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
8.5
14.8
32
40
XA800
NOMESCO Finland
Neuropsychological investigation
5.0
14.8
48
104
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
21.9
14.8
21
10
N03AX14
ATC
levetiracetam; systemic
8.0
14.7
33
44
N29
ICPC
Neurological sympt/complt other
8.5
13.5
29
36
L03AB07
ATC
interferon beta-1a; parenteral
26.6
13.4
18
7
N03AF02
ATC
oxcarbazepine; oral
6.4
13.4
35
58
H27.0
ICD-10 Finland
Aphakia
51.4
12.9
15
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.6
12.8
37
70
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.8
12.6
54
154
L03AX13
ATC
glatiramer acetate; parenteral
25.1
12.5
17
7
H50.30
ICD-10 Finland
Intermittent esotropy
21.9
12.1
17
8
L28
ICPC
Limited function/disability (L)
2.9
12.0
79
307
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.2
11.8
45
115
N03AE01
ATC
clonazepam; systemic
4.4
11.6
42
102
164
Kela drug reimbursment
Fingolimod
66.5
11.6
13
*
H53.1
ICD-10 Finland
Subjective visual disturbances
4.4
11.3
41
100
G91.1
ICD-10 Finland
Obstructive hydrocephalus
44.3
11.0
13
*
N17
ICPC
Vertigo/dizziness
3.2
10.9
58
196
SPAT1229
SPAT
Assessment of need for aid
3.8
10.9
47
135
353
Kela drug reimbursment
Cladribine and fingolimod
112.2
10.5
11
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
10.9
10.4
19
18
H52.2
ICD-10 Finland
Astigmatism
6.5
10.3
26
42
H52.1
ICD-10 Finland
Myopia
4.7
10.2
34
77
N03AX09
ATC
lamotrigine; oral
4.2
10.1
38
97
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
9.8
132
741
N99
ICPC
Neurological disease other
13.7
9.7
16
12
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.2
9.6
51
173
N03AX12
ATC
gabapentin; oral
2.5
9.4
77
340
N06CA01
ATC
amitriptyline and psycholeptics; systemic
3.0
9.4
54
193
74439
ICD-8 Finland
Congenital anomalies of eye, Cataracta NUD
+∞
9.4
9
*
E70.3
ICD-10 Finland
Albinism
+∞
9.4
9
*
N86
ICPC
Multiple sclerosis
22.2
9.4
13
6
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
8.9
9.4
19
22
H53.0
ICD-10 Finland
Amblyopia ex anopsia
8.0
9.2
20
26
TAB00
NOMESCO Finland
Lumbar puncture
3.6
9.2
41
122
183
Kela drug reimbursment
Lamotrigin and topiramate
11.8
9.1
16
14
N05BA09
ATC
clobazam; oral
11.0
8.8
16
15
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.6
8.8
39
115
R13
ICD-10 Finland
Dysphagia
3.7
8.8
38
110
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.7
8.8
64
263
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
8.7
108
579
H50.1
ICD-10 Finland
Divergent concomitant strabismus
11.9
8.6
15
13
37300
ICD-8 Finland
Strabismus, Concomitans convergens
20.4
8.5
12
6
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.5
8.5
71
317
N28
ICPC
Limited function/disability (N)
8.8
8.4
17
20
4AA23
NOMESCO Finland
NA
+∞
8.3
8
*
78112
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Nystagmus
+∞
8.3
8
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
11.0
8.3
15
14
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
33.9
8.1
10
*
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
9.1
8.1
16
18
XCD10
NOMESCO Finland
Electrophysiological examination of eye
6.0
8.1
21
36
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
8.0
173
1144
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.7
7.8
54
218
H50.8
ICD-10 Finland
Other specified strabismus
45.7
7.7
9
*
L04AA27
ATC
fingolimod; oral
45.7
7.7
9
*
R51.80
ICD-10 Finland
Headache
2.2
7.7
80
396
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
7.7
64
285
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
5.1
7.7
23
47
DFF59
NOMESCO Finland
Other assessment of balance
12.1
7.6
13
11
N18
ICPC
Paralysis/weakness
6.3
7.6
19
31
M03BX01
ATC
baclofen; systemic
6.3
7.6
19
31
L04AA31
ATC
teriflunomide; oral
25.4
7.6
10
*
G44.2
ICD-10 Finland
Tension-type headache
2.4
7.4
67
310
H46
ICD-10 Finland
Optic neuritis
11.1
7.3
13
12
A28
ICPC
Limited function/disability NOS
2.4
7.3
64
292
Z31.5
ICD-10 Finland
Genetic counselling
3.1
7.2
38
129
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.0
7.2
22
46
N03AG01
ATC
valproic acid; systemic, rectal
3.1
7.2
39
135
DFF00
NOMESCO Finland
Pure tone audiometry
2.9
7.2
43
159
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
12.3
7.1
12
10
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
12.3
7.1
12
10
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
9.0
7.1
14
16
N03AX11
ATC
topiramate; oral
5.1
7.0
21
43
R4120
NOMESCO Finland
Occupational therapy
2.9
6.8
40
147
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
40.6
6.8
8
*
R3120
NOMESCO Finland
Training in mobility skills
40.6
6.8
8
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
3.1
6.7
35
119
3503
FHL
Single muscle retroposition
22.8
6.7
9
*
H57.1
ICD-10 Finland
Ocular pain
6.6
6.7
16
25
N03AX18
ATC
lacosamide; systemic
12.5
6.6
11
9
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
12.5
6.6
11
9
R53
ICD-10 Finland
Malaise and fatigue
2.0
6.6
90
500
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.3
6.5
31
99
7433A
ICD-9 Finland
Congenital anomalies of eye, Congenital cataract and lens anomalies
70.6
6.4
7
*
CE2W4
NOMESCO Finland
Eye movement mapping
70.6
6.4
7
*
N06AX11
ATC
mirtazapine; oral
1.8
6.4
130
829
XCD00
NOMESCO Finland
Clinical examination of eye in general anaesthesia
+∞
6.3
6
*
H54.0
ICD-10 Finland
Blindness, binocular
+∞
6.3
6
*
R4110
NOMESCO Finland
Physiotherapy
1.8
6.2
121
759
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
27.0
6.2
8
*
TPH04
NOMESCO Finland
Cathetrisation of vein
1.9
6.2
96
558
R1250
NOMESCO Finland
Evaluation of functional capability
4.6
6.2
20
45
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.2
6.2
64
316
N06AX16
ATC
venlafaxine; oral
2.2
6.1
65
324
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
12.7
6.1
10
8
F83
ICD-10 Finland
Mixed specific developmental disorders
5.3
6.1
17
33
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
10.2
6.1
11
11
H52.0
ICD-10 Finland
Hypermetropia
4.7
6.0
19
42
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.4
6.0
48
209
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
197
1016
2.55
21.72
2.5
2.1
216.1
251.3
u/l
0.16
187
962
27
38
7.45
18.39
2.7
1.4
—
—
—
0
0
21
22
9.92
17.99
2.3
1.4
—
—
—
0
0
279
1823
2.20
16.44
9.1
8.3
1.2
1.2
mmol/l
0.77
237
1566
40
97
4.39
15.39
1.8
2.3
17.3
6.4
e6/l
0.62
29
73
40
97
4.39
15.39
1.9
2.4
203.0
158.0
e6/l
0.08
29
76
22
31
7.37
14.93
1.1
1.0
—
—
—
0
0
26
44
6.18
14.92
1.1
1.1
—
—
—
0
0
26
46
5.90
14.27
1.1
1.1
—
—
—
0
0
95
423
2.54
13.56
1.9
2.2
364.8
375.2
nmol/l
0.19
87
399
252
1683
2.00
12.91
8.8
8.2
1.2
1.2
mmol/l
0.11
227
1540
16
5
32.96
12.64
3.3
1.2
—
—
—
0
0
13
12
11.09
12.00
1.2
1.2
—
—
—
0
0
13
12
11.09
12.00
1.2
1.1
—
—
—
0
0
29
68
4.46
11.63
1.2
1.1
—
—
—
0
0
18
27
6.88
11.53
1.1
1.0
0.9
1.1
u/l
—
10
14
303
2216
1.93
11.30
6.1
5.7
6.4
6.6
mmol/l
0.72
280
2040
229
1540
1.90
10.94
5.6
5.4
35.8
36.2
g/l
0.54
204
1441
388
3110
2.10
10.84
3.9
3.9
14.6
14.6
pmol/l
0.16
355
2868
12
12
10.22
10.47
1.3
1.3
—
—
—
0
0
21
42
5.17
10.12
1.0
1.1
—
—
—
0
0
12
13
9.43
9.90
1.3
1.2
—
—
—
0
0
13
5
26.61
9.85
1.1
2.4
—
—
—
0
0
15
23
6.69
9.39
1.1
1.2
—
—
—
0
0
267
1948
1.79
9.30
6.6
6.4
13.0
13.5
umol/l
0.12
250
1842
315
2418
1.81
9.20
10.0
9.4
4.0
4.0
e9/l
0.09
276
2091
172
1110
1.84
8.95
2.9
2.5
53.9
54.9
u/l
0.16
158
1030
104
575
2.02
8.57
5.1
5.5
0.8
0.8
mmol/l
0.39
99
547
11
13
8.63
8.49
1.2
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
15
26
5.91
8.37
1.1
1.2
—
—
—
0
0
429
3697
2.11
8.07
5.0
4.5
1.8
2.2
mu/l
0.55
399
3429
221
1594
1.69
7.49
3.2
2.5
79.2
75.0
nmol/l
1.27
207
1452
99
563
1.94
7.47
2.0
1.7
972.5
1202.1
nmol/l
1.96
77
426
194
1356
1.70
7.36
2.3
1.8
97.6
97.0
pmol/l
0.06
119
695
19
46
4.25
7.33
2.6
2.1
807.4
763.6
e6/l
—
9
16
77
403
2.08
7.32
7.5
7.1
2.0
1.5
mmol/l
0.79
71
310
194
1361
1.69
7.23
4.8
3.2
—
—
—
0
0
127
791
1.81
7.20
1.7
1.5
20.0
21.5
nmol/l
0.50
113
680
70
361
2.09
6.91
7.0
6.9
4.9
4.9
kpa
0.07
70
350
76
408
2.02
6.73
7.5
7.0
6.0
5.8
kpa
1.67
76
395
11
18
6.22
6.45
1.1
1.2
—
—
—
0
0
91
530
1.88
6.34
9.5
7.8
1.1
1.1
mmol/l
0.27
83
502
18
47
3.93
6.31
2.2
3.1
14.1
8.2
%
1.64
11
35
15
34
4.52
6.27
1.0
3.3
29.7
26.8
umol/l
0.49
15
34
13
26
5.10
6.25
1.1
1.1
—
—
—
0
0
174
1225
1.64
6.20
3.3
3.1
2.4
2.4
mmol/l
0.18
150
1084
452
4067
2.13
6.12
20.7
13.7
139.5
139.6
mmol/l
0.73
440
3955
185
1327
1.62
6.10
3.9
3.4
28.0
30.9
u/l
1.11
175
1267
42
187
2.36
5.92
1.7
1.7
—
—
—
0
0
452
4080
2.10
5.86
20.7
13.8
3.9
4.0
mmol/l
0.69
437
3959
9
7
13.06
5.60
1.2
1.6
—
—
—
0
0
153
1068
1.62
5.54
4.4
3.1
0.5
0.4
e6/l
0.19
120
778
415
3668
1.76
5.42
4.5
4.0
5.8
5.8
mmol/l
0.10
382
3389
10
18
5.65
5.34
1.3
1.1
1869.7
1709.4
miu/ml
—
10
18
346
2935
1.58
5.17
4.2
4.0
9.6
10.7
mm/h
1.11
321
2705
29
117
2.57
5.05
2.0
1.7
—
—
—
0
0
326
2738
1.54
5.00
4.1
3.2
42.6
42.1
u/l
0.05
306
2588
139
970
1.60
4.96
2.4
2.2
3.3
2.9
mg/l
0.47
121
837
99
636
1.69
4.89
3.9
2.8
0.8
0.9
e6/l
0.01
55
347
54
288
1.98
4.86
2.4
2.3
—
25.1
—
0
13
54
290
1.97
4.77
6.6
5.0
98.1
72.4
ng/l
1.06
46
267
53
284
1.97
4.71
7.7
7.3
24.2
24.0
mmol/l
0.25
48
269
26
103
2.61
4.70
2.2
2.0
180.1
278.0
ug/l
0.74
26
93
342
2922
1.54
4.69
8.4
7.0
82.5
83.6
u/l
0.14
321
2744
89
564
1.70
4.61
1.9
1.9
—
—
—
0
0
7
5
14.16
4.58
1.3
1.6
—
—
—
0
0
72
435
1.76
4.41
6.4
8.9
104.7
104.3
mmol/l
0.31
72
423
7
6
11.80
4.28
1.3
1.5
—
—
—
0
0
88
572
1.65
4.13
3.3
2.4
12.2
13.8
umol/l
1.23
81
531
132
946
1.54
4.11
2.6
2.3
—
—
—
0
0
68
413
1.75
4.10
6.8
5.9
—
—
—
0
0
448
4126
1.81
4.08
18.4
12.1
21.5
21.9
mg/l
0.09
359
3149
92
608
1.63
4.05
4.3
2.9
2.1
2.4
e6/l
0.15
49
320
25
106
2.43
3.96
1.7
2.3
3.3
3.1
g/l
0.23
17
85
97
654
1.60
3.93
3.8
3.7
114.9
606.9
ng/l
1.75
74
457
21
82
2.63
3.93
1.4
1.3
—
—
—
0
0
21
82
2.63
3.93
1.4
1.3
—
—
—
0
0
103
706
1.58
3.89
1.7
1.6
469.9
444.6
pmol/l
0.43
87
603
26
114
2.35
3.84
1.7
2.2
—
—
—
0
0
26
114
2.35
3.84
1.7
2.2
3.5
3.7
g/l
0.54
17
84
26
114
2.35
3.84
1.7
2.2
7.2
7.2
g/l
0.01
17
89
6
5
12.12
3.77
1.2
1.6
—
—
—
0
0
24
103
2.40
3.72
1.3
2.3
9.0
10.3
g/l
1.29
18
92
9
16
5.70
3.67
3.3
1.6
—
—
—
0
0
33
164
2.08
3.63
2.2
1.8
9.2
8.8
u/l
0.06
21
126
226
1840
1.41
3.57
3.8
4.0
—
—
—
0
0
14
46
3.10
3.55
2.2
3.1
—
—
—
0
0
461
4313
1.86
3.55
12.4
9.4
25.3
26.3
u/l
0.76
449
4169
27
126
2.21
3.48
2.1
1.9
—
—
—
0
0
47
271
1.81
3.39
4.6
3.7
1.2
1.2
mmol/l
0.22
37
239
228
1880
1.39
3.25
3.3
2.8
144.3
98.6
ug/l
0.62
213
1756
7
11
6.43
3.19
1.1
1.2
—
—
—
0
0
74
493
1.59
3.14
3.4
2.5
19.8
23.6
%
2.00
65
432
59
372
1.66
3.12
20.1
16.7
1.6
1.2
inr
—
5
63
161
1264
1.40
3.03
3.5
3.2
40.0
30.4
ng/l
0.25
112
766
62
400
1.63
3.01
1.7
1.8
—
—
—
0
0
78
532
1.55
3.00
3.2
2.4
2.4
2.4
g/l
0.23
71
495
119
886
1.45
3.00
3.2
3.6
1278.4
1071.7
ng/l
0.27
103
739
37
209
1.83
2.87
1.5
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
96
2.24
2.87
3.4
10.7
0.6
0.4
u/ml
0.71
11
50
14
53
2.69
2.81
1.5
1.8
—
—
—
0
0
5
6
8.40
2.75
1.2
1.0
—
—
—
0
0
5
6
8.40
2.75
1.2
1.0
—
—
—
0
0
85
603
1.49
2.73
2.9
2.5
2.5
2.4
mmol/l
1.24
70
528
380
3460
1.41
2.70
5.6
5.0
37.9
39.0
mmol/mol
1.69
347
3239
12
43
2.83
2.66
1.3
1.2
—
—
—
0
0
20
94
2.17
2.58
5.9
3.8
4.1
3.9
mmol/l
0.75
20
82
15
62
2.46
2.56
1.5
1.7
—
—
—
0
0
60
404
1.55
2.45
1.8
1.9
—
—
—
0
0
397
3667
1.40
2.38
3.9
3.6
1.3
1.3
mmol/l
0.69
366
3418
391
3603
1.39
2.38
14.4
10.6
88.3
87.0
ml/min/173m2
0.49
330
2878
411
3823
1.42
2.33
4.4
4.0
4.5
4.7
mmol/l
2.65
378
3578
52
352
1.53
2.10
10.5
8.0
1.2
1.1
mmol/l
0.01
41
267
38
239
1.64
2.08
1.9
1.6
24.5
24.2
iu/l
0.01
26
197
17
322
0.51
2.03
1.5
1.5
—
—
—
0
0
223
1927
1.28
2.02
5.3
3.4
0.0
0.0
estimate
0.00
45
374
7
21
3.36
1.97
2.3
2.7
0.1
0.1
nmol/l
—
7
15
60
425
1.47
1.96
4.5
4.1
29.3
31.8
%
1.50
42
290
52
360
1.50
1.91
8.2
11.4
0.7
1.0
mmol/l
0.16
43
284
7
22
3.21
1.88
1.1
1.1
—
—
—
0
0
22
122
1.84
1.87
1.8
1.7
—
266.7
—
0
6
38
248
1.58
1.82
1.7
1.5
—
—
—
0
0
221
1926
1.26
1.82
7.5
4.7
0.0
0.0
estimate
0.50
45
386
7
24
2.94
1.72
1.9
3.3
—
—
—
0
0
404
3800
1.32
1.71
4.4
4.0
1.4
1.5
mmol/l
1.90
373
3548
410
3865
1.33
1.70
4.8
4.4
2.7
2.8
mmol/l
2.04
377
3599
12
56
2.17
1.62
1.2
1.1
—
—
—
0
0
27
167
1.65
1.61
2.4
1.6
—
—
—
0
0
24
146
1.68
1.53
2.2
1.6
1.2
1.2
g/l
0.21
24
141
221
1954
1.23
1.53
5.3
3.5
0.0
0.0
estimate
0.50
42
372
121
1003
1.27
1.47
1.7
1.7
1.4
1.4
mmol/l
0.07
109
873
7
28
2.52
1.45
2.7
2.4
—
—
—
0
0
6
22
2.75
1.43
2.8
1.8
—
—
—
0
0
9
40
2.27
1.40
1.2
1.7
—
—
—
0
0
129
1084
1.26
1.40
1.5
1.4
1.0
1.4
u/ml
0.57
26
267
13
68
1.94
1.34
1.2
1.1
5.0
2.5
u/ml
—
7
30
413
3932
1.28
1.33
20.0
13.6
40.4
40.1
%
0.36
285
3120
13
69
1.91
1.29
1.7
1.4
—
—
—
0
0
107
890
1.26
1.27
2.1
2.3
1.4
1.2
mg/l
0.32
79
681
47
348
1.39
1.26
4.1
3.0
—
—
—
0
0
14
80
1.77
1.14
3.1
3.5
5.8
4.2
e9/l
0.35
14
80
8
40
2.02
1.12
1.1
1.7
—
—
—
0
0
8
40
2.02
1.12
1.1
1.7
—
—
—
0
0
8
40
2.02
1.12
1.1
1.7
—
—
—
0
0
381
3618
1.22
1.11
21.7
15.1
13.6
13.5
%
0.58
371
3556
14
81
1.75
1.10
3.1
3.7
61.5
56.5
%
0.70
14
81
10
180
0.55
1.09
1.2
1.4
—
—
—
0
0
10
180
0.55
1.09
1.2
1.4
—
—
—
0
0
10
180
0.55
1.09
1.2
1.4
—
—
—
0
0
10
180
0.55
1.09
1.2
1.4
—
—
—
0
0
8
147
0.54
1.05
1.5
1.6
—
—
—
0
0
7
34
2.07
1.03
2.3
1.1
—
—
—
0
0
30
214
1.43
1.02
2.4
2.2
949.7
3216.1
u/l
—
7
84
5
110
0.45
1.01
1.4
1.5
—
—
—
0
0
7
35
2.01
1.00
3.0
4.6
100.3
95.1
%
—
7
35
32
431
0.72
0.98
1.4
1.6
—
—
—
0
0
26
186
1.42
0.89
2.7
3.0
0.2
0.1
e6/l
0.33
26
180
8
42
1.92
0.89
1.3
1.5
—
—
—
0
0
14
87
1.63
0.88
2.1
1.4
—
—
—
0
0
20
136
1.49
0.87
1.2
1.2
—
—
—
0
0
15
96
1.58
0.85
1.6
1.8
—
—
—
0
0
118
1037
1.18
0.82
5.8
3.8
0.0
0.0
estimate
0.50
43
377
6
32
1.88
0.82
1.2
1.3
—
68.0
—
0
5
31
406
0.75
0.82
1.7
1.7
—
—
—
0
0
44
546
0.79
0.78
3.3
2.7
0.6
0.7
ug/l
0.42
30
327
166
1505
1.15
0.78
5.7
3.5
—
—
—
0
0
5
24
2.09
0.74
1.4
1.8
0.6
8.1
u/field
—
5
17
5
24
2.09
0.74
11.4
8.4
0.6
0.6
mmol/l
—
5
24
7
39
1.81
0.72
2.4
3.4
2.2
3.1
nmol/l
—
7
39
103
906
1.17
0.71
3.2
2.9
2575.8
5733.5
umol/l
0.59
94
798
18
126
1.44
0.71
1.9
2.6
—
—
—
0
0
9
144
0.62
0.70
1.3
1.6
—
—
—
0
0
79
682
1.19
0.68
1.2
1.3
11.7
30.4
iu/ml
3.69
17
209
5
27
1.86
0.68
1.0
2.9
16829.8
743.8
u/ml
—
5
27
5
27
1.86
0.68
1.0
1.4
—
—
—
0
0
13
190
0.68
0.66
1.5
1.5
—
—
—
0
0
8
129
0.61
0.64
1.5
1.7
—
—
—
0
0
20
146
1.38
0.64
1.5
1.4
—
—
—
0
0
14
95
1.49
0.64
1.3
1.3
—
—
—
0
0
8
49
1.64
0.62
1.0
1.0
1.6
1.4
g/l
—
8
44
5
30
1.67
0.61
1.4
1.6
—
—
—
0
0
0
21
0.00
0.60
0.0
2.0
—
—
—
0
0
8
52
1.55
0.59
1.1
1.3
0.7
0.5
nmol/l
—
8
45
0
23
0.00
0.58
0.0
1.2
—
—
—
0
0
27
335
0.79
0.52
1.2
1.3
92.5
139.3
iu/ml
—
10
136
55
475
1.18
0.50
4.5
3.6
7.4
7.6
umol/l
0.04
37
411
25
311
0.79
0.49
1.6
1.6
—
—
—
0
0
7
108
0.64
0.49
2.6
1.4
—
—
—
0
0
17
128
1.34
0.48
1.4
1.3
—
—
—
0
0
14
102
1.38
0.47
1.4
1.4
—
—
—
0
0
20
254
0.78
0.47
1.3
1.3
—
—
—
0
0
12
164
0.72
0.46
1.5
1.6
—
—
—
0
0
13
95
1.38
0.44
1.5
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
8
59
1.36
0.41
1.4
1.3
—
—
—
0
0
11
79
1.40
0.41
1.6
3.9
25.0
28.2
mg/l
—
5
50
0
17
0.00
0.40
0.0
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
2.0
—
—
—
0
0
5
35
1.43
0.39
24.8
17.5
1126.6
1443.7
nmol/l
—
5
35
0
19
0.00
0.39
0.0
1.9
—
—
—
0
0
16
124
1.30
0.39
1.0
1.2
0.4
3.7
u/ml
—
10
67
21
170
1.25
0.37
1.4
1.9
—
—
—
0
0
18
143
1.27
0.37
1.2
1.3
—
—
—
0
0
60
537
1.13
0.36
2.0
1.8
1.8
1.4
%
1.44
53
480
12
91
1.33
0.34
2.6
2.6
—
—
—
0
0
8
62
1.29
0.28
1.1
1.1
—
—
—
0
0
33
290
1.15
0.27
2.1
2.6
84.5
71.0
ml/min/173m2
0.88
13
120
9
73
1.24
0.25
1.2
1.8
—
—
—
0
0
28
318
0.87
0.25
4.2
3.9
2.7
21.1
ug/l
0.75
21
257
5
39
1.28
0.23
4.4
2.9
18.8
58.8
u/ml
—
5
39
11
88
1.26
0.22
1.3
1.8
—
—
—
0
0
91
858
1.07
0.22
5.7
3.6
1.0
1.0
kg/l
0.37
14
120
30
267
1.13
0.22
1.1
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.4
—
2.7
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
8
101
0.79
0.21
2.0
1.7
—
105.9
—
0
17
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
11
89
1.24
0.21
2.0
1.8
160.0
227.5
pmol/l
1.37
11
84
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
61
654
0.92
0.21
1.3
1.3
1.3
6.7
u/ml
2.73
23
261
6
52
1.16
0.19
1.3
1.9
—
—
—
0
0
75
710
1.07
0.17
1.5
1.5
—
—
—
0
0
7
63
1.11
0.17
1.3
1.8
—
—
—
0
0
40
371
1.08
0.15
2.5
2.2
28.2
32.2
u/l
0.57
31
314
11
129
0.85
0.15
1.2
1.1
—
—
—
0
0
7
88
0.79
0.14
1.6
1.3
—
31.1
—
0
10
10
84
1.19
0.14
1.0
1.1
1.0
27.3
iu/ml
—
5
23
67
700
0.95
0.12
2.2
2.1
—
—
—
0
0
101
1042
0.96
0.11
1.7
1.7
—
—
—
0
0
5
44
1.14
0.10
1.0
1.2
—
—
—
0
0
5
44
1.14
0.10
1.0
1.0
—
—
—
0
0
5
45
1.11
0.10
1.6
2.9
15.6
21.0
ug/l
—
5
45
13
116
1.12
0.09
1.3
1.9
—
—
—
0
0
6
55
1.09
0.09
3.0
1.4
—
—
—
0
0
6
55
1.09
0.09
3.0
1.4
—
—
—
0
0
6
56
1.07
0.08
3.0
1.4
—
—
—
0
0
6
56
1.07
0.08
3.0
1.4
—
—
—
0
0
6
56
1.07
0.08
3.0
1.4
—
—
—
0
0
70
723
0.96
0.08
4.0
4.1
23.1
21.4
%
0.30
25
321
7
66
1.06
0.08
1.6
1.8
—
—
—
0
0
6
74
0.81
0.07
1.2
1.3
2.0
3.4
ug/l
—
6
64
8
75
1.07
0.07
1.9
1.3
—
—
—
0
0
7
83
0.84
0.07
2.1
1.5
—
—
—
0
0
13
118
1.10
0.07
1.2
1.9
—
—
—
0
0
8
91
0.88
0.07
2.1
2.0
—
—
—
0
0
14
128
1.10
0.06
2.1
1.8
51.1
35.4
nmol/l
1.18
14
122
12
110
1.09
0.05
1.4
1.6
284.2
193.0
u/ml
—
5
59
62
635
0.97
0.05
2.2
1.9
—
—
—
0
0
12
130
0.92
0.04
1.2
1.1
—
—
—
0
0
93
914
1.02
0.04
4.4
4.5
1.6
2.4
ug/l
1.26
87
821
12
113
1.06
0.01
1.4
1.6
—
—
—
0
0
11
104
1.06
0.00
1.7
1.7
—
—
—
0
0
17
165
1.03
0.00
1.3
1.4
263.9
267.9
miu/ml
—
7
87
313
3125
1.00
0.00
3.1
3.5
—
—
—
0
0
6
64
0.94
0.00
3.5
2.5
4.1
12.2
u/ml
—
6
57
5
54
0.92
0.00
1.4
1.6
—
—
—
0
0
7
70
1.00
0.00
2.6
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
5
56
0.89
0.00
3.4
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_NYSTAGMUS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_NYSTAGMUS | 1.772 [1.39, 2.25] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.166 |
During the follow-up period (1.1.1998 — 31.12.2019), 175 out of 1946 females with H7_NYSTAGMUS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_NYSTAGMUS | 2.021 [1.62, 2.52] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 210 out of 2046 males with H7_NYSTAGMUS died.
Mortality risk
Mortality risk for people of age
years, who have H7_NYSTAGMUS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.126% | 0.334% |
| 5 | 1.05% | 2.326% |
| 10 | 2.605% | 5.471% |
| 15 | 4.768% | 10.192% |
| 20 | 8.138% | 17.425% |
Relationships between endpoints
↥Index endpoint: H7_NYSTAGMUS – Nystagmus and other irregular eye movements
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data